1. A graminan type fructan from Achyranthes bidentata prevents the kidney injury in diabetic mice by regulating gut microbiota.
- Author
-
Si H, Chen Y, Hu D, Yao S, Yang J, and Wen X
- Subjects
- Animals, Mice, Male, Mice, Inbred C57BL, Diet, High-Fat adverse effects, Streptozocin, Kidney drug effects, Kidney pathology, Fatty Acids, Volatile metabolism, Gastrointestinal Microbiome drug effects, Achyranthes chemistry, Diabetes Mellitus, Experimental drug therapy, Diabetes Mellitus, Experimental complications, Diabetic Nephropathies drug therapy, Diabetic Nephropathies prevention & control, Fructans pharmacology, Fructans chemistry
- Abstract
Diabetic kidney disease (DKD) is the main cause of end-stage renal disease, and few therapeutic options are available. The root of Achyranthis bidentatae (AB) is commonly used for DKD treatment in Traditional Chinese medicine. However, its mechanisms are still unclear. Here, a graminan type fructan ABPW1 with molecular weight of 3998 Da was purified from AB. It was composed of β-1,2-linked Fruf, β-2,6-linked-Fruf and β-1,2,6-linked-Fruf backbone, and terminated with T-Glcp and 2-Fruf residues. ABPW1 protected against kidney injuries and intestinal barrier disruption in Streptozotocin (STZ)/High fat diet (HFD) mice. It could modulate gut microbiota composition, evidenced by a rise in the abundance of Bacteroide and decreases of Rikenella, Alistipes, Laedolimicola and Faecalibaculum. ABPW1 intervention promoted short chain fatty acids (SCFAs) production in STZ/HFD mice, especially propionate and isobutyric acid. Antibiotic treatment further demonstrated the key role of gut microbiota in the renal protective action of ABPW1. In addition, in vitro simulated digestion and fermentation together with in vivo fluorescent labeling studies demonstrated ABPW1 was indigestible in upper digestive tract but could reach the colon and be degraded into SCFAs by gut microbiota there. Overall, these data suggested ABPW1 has the potential application on DKD prevention., Competing Interests: Declaration of competing interest All authors wish to confirm that there are no known conflicts of interest associated with this publication., (Copyright © 2024. Published by Elsevier Ltd.)
- Published
- 2024
- Full Text
- View/download PDF